Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. announced that England's National Institute for Health and Care Excellence (NICE) has recommended Kapruvia® for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis. The decision follows authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in April 2022. MHRA approval and the NICE recommendation were supported by positive data from two pivotal phase-III trials KALM-1, conducted in the U.S. (New England Journal of Medicine 2020; 382:222-232), and the global KALM-2, as well as supportive data from an additional 32 clinical studies.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.725 USD | -3.37% | -8.48% | -2.42% |
05-13 | Earnings Flash (CARA) CARA THERAPEUTICS Posts Q1 Revenue $2.1M, vs. Street Est of $1.7M | MT |
05-13 | Cara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.42% | 41.02M | |
-2.47% | 89.37B | |
+2.76% | 40.65B | |
-13.78% | 32.81B | |
+51.84% | 25B | |
-16.77% | 15.29B | |
-42.60% | 11.61B | |
-10.48% | 11.49B | |
+5.84% | 8.98B | |
-7.72% | 8.23B |
- Stock Market
- Equities
- CARA Stock
- News Cara Therapeutics, Inc.
- Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. Announces England’s National Institute for Health and Care Excellence has Recommended Kapruvia